Related Experiment Videos
Erectile dysfunction: oral pharmacotherapy options.
1University Hospital Center Rijeka, Department of Pharmacology, University of Rijeka Medical School, Croatia. Dinko.Vitezic@mamed.medri.hr
International Journal of Clinical Pharmacology and Therapeutics
|October 3, 2002
Summary
Sildenafil is a highly effective oral treatment for erectile dysfunction (ED), improving patient quality of life and relationships. It offers an acceptable risk-benefit ratio as a first-line therapy for ED.
Area of Science:
- Urology
- Pharmacology
- Men's Health
Background:
- Erectile dysfunction (ED) affects 52% of men aged 40-70, impacting relationships.
- ED can be psychogenic, organic, or mixed, necessitating effective treatment.
- Oral drug therapy offers a convenient solution for ED management.
Purpose of the Study:
- To review the efficacy and safety of sildenafil for erectile dysfunction.
- To discuss the role of phosphodiesterase type 5 (PDE-5) inhibitors in ED pharmacotherapy.
- To evaluate the impact of sildenafil on patient and partner quality of life.
Main Methods:
- Review of existing studies on sildenafil and other oral ED medications.
- Analysis of adverse effects and contraindications associated with sildenafil.
- Assessment of sildenafil's safety in patients with cardiovascular disease (without nitrates).
Main Results:
- Sildenafil is effective for ED of various etiologies and improves partnership quality.
- Common side effects (headache, flushes, dyspepsia) are dose-related, mild, and transient.
- Sildenafil is safe and effective in patients with cardiovascular disease not taking nitrates.
Conclusions:
- PDE-5 inhibition is central to oral ED pharmacotherapy, with sildenafil as a first-line option.
- Sildenafil significantly improves quality of life for patients and partners.
- Further studies are needed for other oral ED agents, but sildenafil offers a favorable risk-benefit ratio.